Trastuzumab Deruxtecan in Advanced Breast Cancer

Recruiting now

Conditions studied: Advanced Breast Cancer

In brief

To evaluate the efficacy and safety of trastuzumab deruxtecan in advanced breast cancer patients.

Key facts

Study ID

NCT07180264

Run by

Wenjin Yin

People needed

118

Starts

2025-08-28

Expected to finish

2029-02-01

Last updated by the study team

2025-11-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Aged ≥18 and older
• Breast cancer patients meeting current guideline recommendations and planning to receive trastuzumab deruxtecan
• ECOG 0-1

You may not qualify if…

• During pregnancy and lactation

Where it is running

• Renji Hospital, School of Medicine, Shanghai Jiaotong University — Shanghai, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.